

8:30	Welcome and registration of participants
9:00	Opening words
<b>SESSION 1 9:15 – 10:45</b>	<b>TUMOUR MICROENVIRONMENT AND INTEGRATED BIOMARKER SIGNATURES PREDICTING ANTI-PD-1 RESPONSE</b>
9:15	Tracking preexisting anti-tumor CD8+T cells to predict clinical response to the blocking of PD-1/PD-L1 axis <b>Éric TARTOUR</b> • Paris
9:35	Biomarker Signature in NSCLC Treated with Pembrolizumab <b>Alba DIAZ HERRERO</b> • Paris
9:55	Validation of a Predictive Immune Signature of Response to Second-Line Anti-PD-1 Immunotherapy in Metastatic Non-Small Cell Lung Cancer <b>Stéphanie CORGNAC</b> • Villejuif
10:15	INTEGRative Analysis of Biomarkers and Regulatory Mechanisms of Response to Adjuvant Immunotherapy in Melanoma: Dissecting Tumor, Immune, and Stromal Ecosystem Heterogeneity <b>Stéphane DALLE</b> • Lyon
10:35	<b>Short talk:</b> Circulating Anti-ANXA2 Antibodies as Predictive Biomarkers of Response to Anti-PD-1 Therapy <b>Aurélien MARABELLE</b> • Villejuif
10:45 – 11:15	Coffee break
<b>SESSION 2 11:15 – 12:30</b>	<b>CAR-T CELLS AND CIRCULATING BIOMARKER SIGNATURES IN IMMUNOTHERAPY</b>
11:15	T-Cell Intrinsic and Tumor Microenvironment Determinants of CAR-T Cell Response in Lymphoma <b>Suman MITRA</b> • Lille
11:35	Peripheral Blood Extracellular Vesicle (miRNA) Signatures Predicting Immunotherapy Response in Lung Cancer <b>Delphine FRADIN</b> • Nantes
11:55	Made'IT: Soluble MAdCAM as a Biomarker of Gut Dysbiosis Associated with Immunotherapy Resistance in Cancer <b>Lisa DEROSA</b> • Villejuif
12:15	<b>Short talk:</b> Functional fitness of pre-treatment T cells as signature to predict CAR-T cell therapy efficacy in LBCL patients <b>Loïc DUPRE</b> • Toulouse
12:30 – 13:30	Lunch break

<b>13:30 – 14:30</b>	<b>POSTER VIEWING</b>
<b>SESSION 3 14:30 – 15:40</b>	<b>MULTIMODAL BIOMARKERS IN RADIO-IMMUNOTHERAPY: FROM IMAGING TO GENOMICS</b>
14:30	Artificial Intelligence-Driven Integration of Radiomics, Pathomics and Genomics to Predict Immunotherapy Outcomes <b>Éric DEUTSCH</b> • Villejuif
14:50	Integrated bio-imaging markers of response to hypofractionated stereotatic irradiation and anti-PDL1 Durvalumab combination in patients with recurrent glioblastoma <b>Elizabeth MOYAL</b> • Toulouse
15:10	Biomarkers of Response to Combined Radiotherapy and Pembrolizumab in Locally Advanced Head and Neck Cancers: Results from the Randomized Phase II GORTEC 2015-01 PembroRad Trial <b>Julian BIAU</b> • Clermont-Ferrand
15:30	<b>Short talk:</b> Predictive Factors of Nivolumab Efficacy Combined with Adjuvant Radiotherapy-Cisplatin in Resected High-Risk Head and Neck Squamous Cell Carcinoma: Ancillary Study of the Randomized GORTEC 2018-01 NIVO POST-OP Trial (NCT03576417) <b>Esma SAADA-BOUZID</b> • Nice
15:40 – 16:10	Coffee break
<b>SESSION 4 16:10 – 16:50</b>	<b>MOLECULAR AND SPATIAL DETERMINANTS OF RESISTANCE TO IMMUNE CHECKPOINT INHIBITORS</b>
16:10	Genetic/Epigenetic biomarkers of primary resistance to anti-PD1 therapy in recurrent/metastatic HNSCC <b>Edith BORCOMAN</b> • Paris
16:30	Spatial Organization of the Tumor Immune Microenvironment as a Biomarker of Response to Combined Chemotherapy and Immunotherapy in Fragile Patients with Recurrent Head and Neck Squamous Cell Carcinoma <b>Pierre SAINTIGNY</b> • Lyon
16:50	<b>Short talk:</b> Spatial Organization of Immune Cells as a Predictor of Immunotherapy Response in Triple-Negative Breast Cancer Resistant to Neoadjuvant Chemotherapy <b>Christophe CAUX</b> • Lyon
<b>17:00</b>	<b>KEYNOTE LECTURE: High Endothelial Venules and Tumor Immune Entry: New Concepts for Enhancing Immunotherapy Efficacy</b> <b>Jean-Philippe GIRARD</b> • Toulouse
17:45	Closing Session